ストックスクリーナーアプリを入手
41.83
6.28%
2.47
アフターアワーズ：
41.82
-0.010
-0.02%
前日終値:
$39.36
開ける：
$41.6
24時間の取引高:
11.87M
Relative Volume:
1.07
時価総額：
$16.34B
収益：
$3.14B
当期純損益:
$-3.36B
株価収益率:
-4.7915
EPS:
-8.73
ネットキャッシュフロー:
$-4.03B
1週間 パフォーマンス:
+21.95%
1か月 パフォーマンス:
+39.95%
6か月 パフォーマンス:
+30.47%
1年 パフォーマンス:
+23.90%
1日の値動き範囲:
$40.55
$42.39
1週間の範囲:
$32.37
$42.39
52週間の値動き範囲:
$22.28
$45.40
Moderna Inc Stock (MRNA) Company Profile
MRNA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
41.83 | 15.38B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-07 | 再開されました | UBS | Neutral |
| 2025-12-12 | 開始されました | Jefferies | Hold |
| 2025-03-13 | 開始されました | Citigroup | Neutral |
| 2025-02-18 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-01-29 | ダウングレード | Goldman | Buy → Neutral |
| 2024-12-18 | ダウングレード | Argus | Buy → Hold |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-19 | 開始されました | Berenberg | Hold |
| 2024-11-18 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-09-13 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2024-09-13 | ダウングレード | Jefferies | Buy → Hold |
| 2024-09-13 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-08-28 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-08-07 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-08-05 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2024-01-02 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 開始されました | Canaccord Genuity | Hold |
| 2023-11-03 | アップグレード | HSBC Securities | Reduce → Hold |
| 2023-11-02 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2023-08-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 開始されました | William Blair | Mkt Perform |
| 2023-07-14 | 開始されました | HSBC Securities | Reduce |
| 2023-06-26 | アップグレード | UBS | Neutral → Buy |
| 2023-04-26 | 開始されました | Guggenheim | Neutral |
| 2023-03-13 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-02-24 | ダウングレード | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | アップグレード | Jefferies | Hold → Buy |
| 2022-12-14 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | アップグレード | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | アップグレード | Deutsche Bank | Hold → Buy |
| 2022-02-01 | アップグレード | Redburn | Sell → Neutral |
| 2022-01-26 | アップグレード | Deutsche Bank | Sell → Hold |
| 2022-01-21 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 開始されました | UBS | Neutral |
| 2021-12-07 | 開始されました | Cowen | Market Perform |
| 2021-11-09 | 開始されました | Wolfe Research | Outperform |
| 2021-10-22 | 開始されました | Deutsche Bank | Sell |
| 2021-10-15 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-08-06 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 繰り返されました | Jefferies | Hold |
| 2021-02-01 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-12-16 | ダウングレード | Jefferies | Buy → Hold |
| 2020-12-16 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | ダウングレード | Needham | Buy → Hold |
| 2020-11-23 | 開始されました | Wells Fargo | Equal Weight |
| 2020-11-17 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-07-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 開始されました | Jefferies | Buy |
| 2020-06-30 | 開始されました | Argus | Buy |
| 2020-06-08 | 開始されました | Barclays | Overweight |
| 2020-04-30 | 開始されました | BMO Capital Markets | Outperform |
| 2020-03-05 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 再開されました | BofA/Merrill | Buy |
| 2019-10-25 | 開始されました | ROTH Capital | Buy |
| 2019-04-05 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Moderna Inc (MRNA) 最新ニュース
Moderna Shares Surge Amid Positive Earnings and Regulatory News - StocksToTrade
Moderna’s Market Gains as Revenue Projections Boost Investor Confidence - timothysykes.com
Moderna stock price pops 6% into the weekend — here’s what traders are watching next for MRNA - TechStock²
OVERSEA CHINESE BANKING Corp Ltd Sells 37,172 Shares of Moderna, Inc. $MRNA - MarketBeat
CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate - The Daily News Journal
Moderna, Inc. (NASDAQ:MRNA) Given Average Rating of "Reduce" by Analysts - MarketBeat
Moderna (NASDAQ:MRNA) Upgraded at Wall Street Zen - MarketBeat
Moderna Stock vs Competition: Who Wins? - Trefis
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference - The Register-Guard
Weekly Market Update: Stocks Remain Flat as Consumer Defensives Rise and Financial Services Fall - morningstar.com
I Hope Moderna (MRNA) Posts Growth, Says Jim Cramer - Finviz
Moderna (NASDAQ:MRNA) Shares Gap UpStill a Buy? - MarketBeat
Moderna's Fourth Quarter 2025 Financial Results: Anticipated Highlights - Bitget
The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026 - FinancialContent
Arbutus falls as patent dispute with Moderna hits EU snag - Seeking Alpha
Moderna's Q4 2025 Earnings: What to Expect - Yahoo Finance
Best Biotech Stocks To Keep An Eye OnJanuary 15th - MarketBeat
Moderna Stock on the Move: What Sparked the 13% Jump in the Past Week? - Finviz
Analysts Set Expectations for Moderna FY2030 Earnings - MarketBeat
Non-covid mRNA Vaccine and Therapeutics Market Exclusive Report on the Latest Revenue and Future Scope - openPR.com
Aug Drivers: Is Moderna Inc a turnaround story2025 Trading Recap & Weekly Stock Breakout Alerts - baoquankhu1.vn
Moderna projects 10% growth next year; lifts outlook for year-end liquidity - MSN
Moderna (MRNA) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot - FinancialContent
Moderna (MRNA) Stock: Biotech Leader Surges 30% on Updated Guidance - Blockonomi
Moderna (MRNA) rockets 17% on strong preliminary FY25 results - MSN
Moderna (MRNA) Rockets 17% on Strong Preliminary FY25 Results - Insider Monkey
Moderna Inc.: From Pandemic Phenomenon to mRNA Platform Powerhouse - AD HOC NEWS
Building Companies Like Experiments: The Flagship Pioneering Model - Citeline News & Insights
Trending tickers: Nvidia, Intel, Moderna, BP and Vistry - Yahoo Finance UK
Moderna (MRNA) Stock: Biotech Breaks Out With 30% Rally in 2026 - CoinCentral
Moderna 2026 at JPM 2026: Projects $1.9B Revenue and Eyes Vaccine Approvals - geneonline.com
Intel, Moderna, Adobe, BitMine Immersion And Strategy: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
JPM26: Biotech’s M&A lift, the ‘new’ Biogen and Merck’s $70B target - BioPharma Dive
Moderna Eyes Higher Revenue and Strategic Approvals at J.P. Morgan Event - timothysykes.com
Adobe stock downgraded, Moderna surges on upbeat guidance - Yahoo Finance
Moderna (NASDAQ:MRNA) Shares Up 7.1%Still a Buy? - MarketBeat
Moderna rallies after projecting better-than-expected 2025 sales - Sherwood News
Why Moderna Stock Strength Is Only Beginning: Technical Analysis - Barron's
Silver Jumps To $89 After Soft CPI, JPMorgan Falls 3%: What's Moving Markets Tuesday? - Benzinga
Moderna (MRNA) Shares Surge by Nearly 13% - GuruFocus
Moderna, Kosmos Energy, Option Care Health, Kennametal And Other Big Stocks Moving Higher On Tuesday - Benzinga
Moderna stock jumps 12% after $1.9 billion 2025 sales view — what investors watch next - TechStock²
Moderna jumps 12% after 2025 projections - breakingthenews.net
Moderna: V940/Keytruda Data And Vaccine Revenues Drive A High-Risk Recovery Story (MRNA) - Seeking Alpha
Moderna updates 2025 outlook and highlights pipeline progress - The Globe and Mail
Moderna says possible allergic reactions to Covid-19 vaccine under investigation - The Daily Star
Moderna chair says US assault on science is just beginning - The Daily Gazette
Commonwealth Fusion Systems Appoints Stephane Bancel, Moderna CEO, to Its Board of Directors - energynews
The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape - FinancialContent
Moderna Chair Says US Assault on Science Is Just Beginning - Bloomberg
Moderna Inc (MRNA) 財務データ
収益
当期純利益
現金流量
EPS
4.73%
0.92%
大文字化:
|
ボリューム (24 時間):